Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
2021 · Nature Communications · 50 citations
https://doi.org/10.1038/s41467-021-26539-7
M
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
82
Papers
850
Citations
15
h-index
24
i10-index
Meiying Shen is an academic researcher from The Affiliated Yongchuan Hospital of Chongqing Medical University. The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 15, co-authored 70 publications.
ORCID: 0000-0001-8040-2330Papers by this author
worksTargeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer
2024 · Journal of Translational Medicine · 20 citations
https://doi.org/10.1186/s12967-024-05518-8
Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection
2022 · Frontiers in Medicine · 11 citations
https://doi.org/10.3389/fmed.2022.952697
SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2− breast cancer
2024 · Cell Death and Disease · 10 citations
https://doi.org/10.1038/s41419-024-06838-9
Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations
2024 · Cancer Immunology Immunotherapy · 9 citations
https://doi.org/10.1007/s00262-024-03729-y
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy
2024 · Journal of Nanobiotechnology · 5 citations
https://doi.org/10.1186/s12951-024-02700-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat